In a report released yesterday, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Johnson & Johnson (JNJ – Research Report), with a price target of $215.00. The company’s shares closed yesterday at $155.80.
Chen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Johnson & Johnson, and Merck & Company. According to TipRanks, Chen has an average return of -9.8% and a 38.29% success rate on recommended stocks.
In addition to Cantor Fitzgerald, Johnson & Johnson also received a Buy from DZ BANK AG’s Elmar Kraus in a report issued on January 25. However, on January 24, Guggenheim maintained a Hold rating on Johnson & Johnson (NYSE: JNJ).
See the top stocks recommended by analysts >>
Based on Johnson & Johnson’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $21.35 billion and a net profit of $26.03 billion. In comparison, last year the company earned a revenue of $20 billion and had a net profit of $4.46 billion
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Johnson & Johnson (JNJ) Company Description:
Johnson & Johnson provides healthcare products across three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
Read More on JNJ:
- Senate Health, Education, Labor & Pensions Committee holds a hearing
- U.S. sends offers for drugs selected for price negotiations, NY Times says
- Senate Health, Education, Labor & Pensions Committee holds an executive session
- Nanobiotixachieves $20M milestone payment from Johnson & Johnson subsidiary
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
